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The Role of Toll-Like Receptors in 
Hematopoietic Malignancies
Darlene A. Monlish†, Sima T. Bhatt† and Laura G. Schuettpelz*
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
Toll-like receptors (TLRs) are a family of pattern recognition receptors that shape the innate 
immune system by identifying pathogen-associated molecular patterns and host-derived 
damage-associated molecular patterns. TLRs are widely expressed on both immune 
cells and non-immune cells, including hematopoietic stem and progenitor cells, effector 
immune cell populations, and endothelial cells. In addition to their well-known role in the 
innate immune response to acute infection or injury, accumulating evidence supports 
a role for TLRs in the development of hematopoietic and other malignancies. Several 
hematopoietic disorders, including lymphoproliferative disorders and myelodysplastic 
syndromes, which possess a high risk of transformation to leukemia, have been linked to 
aberrant TLR signaling. Furthermore, activation of TLRs leads to the induction of a num-
ber of proinflammatory cytokines and chemokines, which can promote tumorigenesis 
by driving cell proliferation and migration and providing a favorable microenvironment for 
tumor cells. Beyond hematopoietic malignancies, the upregulation of a number of TLRs 
has been linked to promoting tumor cell survival, proliferation, and metastasis in a variety 
of cancers, including those of the colon, breast, and lung. This review focuses on the 
contribution of TLRs to hematopoietic malignancies, highlighting the known direct and 
indirect effects of TLR signaling on tumor cells and their microenvironment. In addition, 
the utility of TLR agonists and antagonists as potential therapeutics in the treatment of 
hematopoietic malignancies is discussed.
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iNTRODUCTiON
Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that play a central 
role in innate immunity. TLRs are expressed on a wide variety of effector immune and stromal cell 
types, as well as hematopoietic stem and progenitor cells (HSPCs) (1–3), and signaling through 
these receptors is essential to mounting an effective immune response to an acute infection or injury. 
However, while TLR signaling is important to the normal immune response, enhanced or aberrant 
TLR signaling is associated with ineffective hematopoiesis and hematopoietic malignancy (4, 5). 
Most notably, enhanced expression of components of the TLR signaling pathway, as well as activat-
ing mutations in some cases, are associated with lymphoproliferative disorders and myelodysplastic 
syndromes (MDS) (6–16).
This review focuses on the contribution of TLR signaling to impaired hematopoiesis and hemat-
opoietic malignancy. We will explore the role of cell-autonomous aberrant TLR signaling to loss 
of normal HSPC function and leukemogenesis, as well as the non-cell-autonomous effects of TLR 
signaling that may contribute to disease pathogenesis. Finally, we will discuss the utility of TLRs and 
their downstream effectors as therapeutic targets in hematopoietic neoplasms.
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TLR SiGNALiNG OveRview
A total of 12 TLR family members have been described in 
mice, and 10 in humans (17). In addition to identifying foreign 
 pathogen-associated molecular patterns [PAMPS, e.g., pepti-
doglycans, lipopolysaccharide (LPS)], TLRs recognize a wide 
variety of non-pathogen-associated ligands. These so-called 
damage-associated molecular patterns (DAMPS) include various 
endogenous by-products of cellular damage, such as free nucleic 
acids and extracellular matrix components (18). TLRs are widely 
expressed on both immune cells and non-immune cells, including 
dendritic cells, macrophages, lymphocytes, HSPCs, and endothe-
lial cells (3, 19–22). Some of the TLRs are localized to the plasma 
membrane (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11), while 
others are found in endosomes (TLR3, TLR7, TLR8, and TLR9). 
In general, the TLRs act as homodimers, with the exception of 
TLR2, which heterodimerizes with TLR1 or TLR6 (23–25). Each 
TLR has a unique profile of known ligands, dictated in part by 
their subcellular localization.
Signaling through TLRs requires the recruitment of intracel-
lular adaptor proteins, with all TLRs, except TLR3, using the 
myeloid differentiation primary response gene 88 (MyD88). 
Following recruitment of MyD88 to activated TLRs, this adaptor 
complexes with the serine–threonine kinase  interleukin-1 recep-
tor-associated kinase 4 (IRAK4) (26), which in turn recruits other 
IRAK family members (IRAK1 and IRAK2), forming a complex 
referred to as the “Myddosome” (27). IRAK1 interacts with the 
tumor necrosis factor (TNF) R-associated factor 6 (TRAF6) E3 
ubiquitin ligase. TRAF6 then participates in the activation of 
transforming growth factor beta-activated kinase 1 (TAK1), 
which in turn activates the nuclear factor k-light- chain-
enhancer of activated B cells (NF-κB) and mitogen-activated 
protein kinase (MAPK) pathways and promotes the expression 
of various proinflammatory cytokines (e.g., interleukin-1 (IL-1), 
IL-6, IL-8, and TNFα) (28).
Toll-like receptor3 functions independently of MyD88, utiliz-
ing instead the adaptor protein TIR-domain-containing adaptor-
inducing interferon-B (TRIF) (29). TRIF, upon binding to TRAF3, 
recruits the IKK-related kinases TBK1 and IKKε and ultimately 
activates interferon regulatory factor-3 (IRF3) and stimulates the 
production of type I interferons (IFNs) (30). In addition, TRIF 
interacts with TRAF6 and contributes to MyD88-independent 
activation of NF-κB and MAPKs (31). TLR4 uniquely utilizes 
both MyD88- and TRIF-dependent pathways (Figure 1) (32).
TLR SiGNALiNG AND HeMATOPOieTiC 
STeM AND PROGeNiTOR CeLLS
In response to acute infection or injury, TLR signaling promotes 
the production of proinflammatory cytokines and assists with 
the development of the adaptive immune response. Recent 
studies suggest that outside of their well-known role in 
responding to pathogens and other insults by stimulating 
effector immune cells, TLRs can influence hematopoiesis from 
the level of the hematopoietic stem cell (HSC). Both mouse 
and human HSCs express TLRs (1–3), and accumulating data 
demonstrate that TLR ligands can influence the proliferation, 
mobilization, and differentiation of HSCs and committed 
progenitors (2, 4, 5, 33–37). In fact, recent studies have shown 
that proinflammatory signals, including TLR4–MyD88–NF-κB 
stimulation, are necessary for HSPC emergence in zebra fish 
and mouse embryos (38, 39). Thus, TLR signaling contributes 
to early hematopoiesis and continues to influence HSPCs 
into adulthood. Notably, sustained exposure to TLR signals is 
associated with loss of normal HSC function. Chronic in vivo 
treatment of mice with the TLR4 agonist LPS, for example, 
leads to HSC cycling and a promotion of myeloid differentia-
tion with a loss of HSC repopulating activity in transplantation 
experiments (4). Similarly, systemic exposure of mice to the 
TLR2 agonist PAM3CSK4 leads to an expansion of bone marrow 
and spleen phenotypic HSCs, but a loss of bone marrow HSC 
self-renewal (40). Conversely, loss of TLR signaling (in Tlr2−/−, 
Tlr4−/−, Tlr9−/−, or MyD88−/− deficient mice) is associated with 
enhanced HSC repopulating activity (41, 42). This last point 
illustrates that even in the absence of overt infection or other 
insult, TLR signaling regulates baseline hematopoiesis.
The effects of TLR signaling on HSPCs are likely mediated 
by both cell-autonomous and cell non-autonomous mechanisms. 
Evidence for a direct, cell-autonomous role for TLR signaling 
in regulating HSCs comes from in  vitro studies showing that 
incubation of HSPCs with TLR agonists induces cell cycling 
and myeloid differentiation (1, 2). Furthermore, Megias and 
colleagues demonstrated that purified HSPCs (c-Kit+ Sca-1+ 
Lineage− IL7Ra− cells) from wild-type mice transplanted into 
Tlr2−/−, Tlr4−/−, or MyD88−/− recipients differentiated into mac-
rophages in response to specific TLR ligands (37). This approach, 
by removing a potential contribution of soluble mediators of 
the effects of TLR signals from other hematopoietic or stromal 
cells, supports the idea that TLR ligands can have direct, cell-
autonomous effects on HSPCs in  vivo. In agreement with this 
idea, we recently reported that systemic exposure of mice to a 
TLR2 ligand regulates HSCs, in part, via cell-autonomous TLR2 
signaling (40). Chimeric mice were generated in which a mixture 
of Tlr2−/− and WT bone marrow was transplanted into lethally 
irradiated Tlr2−/− recipients. Treatment of these chimeras with 
the TLR2 agonist PAM3CSK4 led to a relatively greater expansion 
of WT HSCs compared to Tlr2−/− HSCs, supporting a role for 
cell-autonomous TLR2 signaling in regulating HSCs.
While in  vitro and chimeric animal studies endorse a role 
for cell-autonomous TLR signaling in the regulation of imma-
ture hematopoietic cells, a large number of proinflammatory 
cytokines are produced by effector immune cells and progenitors 
in response to TLR ligands, and these cytokines are known to 
influence HSPC cycling, differentiation, survival, and function, 
as well (43). For example, several recent studies have shown that 
systemic TLR4 stimulation in mice promotes HSC mobilization 
indirectly via production of granulocyte-colony stimulating 
factor (G-CSF) by endothelial cells (36, 44). Systemic TLR2 
stimulation in mice also leads to G-CSF production, as well as 
increased serum levels of TNFα, and inhibition of these cytokines 
partially rescues the proliferation and mobilization of HSPCs in 
response to TLR2 agonist treatment (40). Finally, using a micro-
fluidic single-cell proteomics platform, Zhao et al. showed that 
TLR2 and TLR4 ligands stimulate abundant cytokine production 
FiGURe 1 | TLR signaling overview. TLR signaling may be divided into the MyD88-dependent and MyD88-independent (TRIF-dependent) signaling pathways. 
In the MyD88-dependent pathway, activation of MyD88 from membrane-bound TLR ligation forms complexes with IRAKs1, 2, and 4, leading to an interaction with 
TRAF6. Ultimately, the NF-κB and MAPK pathways are activated, resulting in the production of inflammatory cytokines. The TRIF-dependent (MyD88-independent) 
pathway requires TRIF binding to TRAF3, which recruits TBK1 and IKKε, thereby activating IRF3. Endosomal TLRs (3, 7, 8, and 9) act through the IRAK–TRAF6 
complex to activate IRF7. Together, IRF3 and IRF7 stimulate type I interferon production.
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by short-term HSCs and multipotent progenitors, which in turn 
promote myeloid differentiation in an autocrine or paracrine 
manner (45). Thus, TLR ligands influence HSPC cycling, dif-
ferentiation, and mobilization both directly, via cell-autonomous 
signaling, and indirectly, via non-cell-autonomous production of 
proinflammatory cytokines.
TLR SiGNALiNG AND HeMATOPOieTiC 
MALiGNANCY
As noted above, sustained or dysregulated TLR signaling, via 
direct cell-autonomous as well as indirect mechanisms involving 
inflammatory cytokines, may contribute to loss of normal HSC 
TABLe 1 | Overview of toll-like receptors associated with hematologic 
malignancies.
Toll-like 
receptor
Hematologic malignancy Reference
TLR1 Myelodysplastic syndrome (MDS), acute 
lymphoblastic leukemia (ALL), acute myeloid 
leukemia (AML), multiple myeloma (MM), 
chronic lymphocytic leukemia (CLL)
MDS: (15, 53); 
ALL: (54); AML: 
(63, 64); MM: (72, 
73); CLL: (75)
TLR2 Myelodysplastic syndrome (MDS), acute 
lymphoblastic leukemia (ALL), acute myeloid 
leukemia (AML), multiple myeloma (MM), 
chronic lymphocytic leukemia (CLL)
MDS: (15, 53, 57, 
59, 60); ALL: (54); 
AML: (62, 64); MM: 
(71, 73); CLL: (75)
TLR3 Acute myeloid leukemia (AML), multiple 
myeloma (MM), indolent non-Hodgkin’s 
lymphoma (iNHL)
AML: (64, 88); MM: 
(72, 73, 87); iNHL: 
(104)
TLR4 Myelodysplastic syndrome (MDS), acute 
myeloid leukemia (AML), multiple myeloma 
(MM), Mantle cell lymphoma (MCL), Follicular 
non-Hodgkin’s lymphoma (NHL)
(11, 52, 57, 59–61); 
AML: (62, 64); MM: 
(71–73); MCL: (74); 
NHL: (103)
TLR5 Acute myeloid leukemia (AML), multiple 
myeloma (MM)
AML: (64); MM: (73)
TLR6 Myelodysplastic syndrome (MDS), acute 
lymphoblastic leukemia (ALL), acute myeloid 
leukemia (AML), multiple myeloma (MM), 
chronic lymphocytic leukemia (CLL)
MDS: (15, 53); ALL: 
(54); AML: (64); 
MM: (73); CLL: (75)
TLR7 Acute myeloid leukemia (AML), activated B-cell 
(ABC) diffuse large B-cell lymphoma (DLBCL), 
multiple myeloma (MM), chronic lymphocytic 
leukemia (CLL)
AML: (64, 86); ABC 
DLBCL: (70); MM: 
(72, 73); CLL: (75)
TLR8 Acute myeloid leukemia (AML), multiple 
myeloma (MM)
AML: (64, 86); MM: 
(72, 73)
TLR9 Acute myeloid leukemia (AML), activated B-cell 
(ABC) diffuse large B-cell lymphoma (DLBCL), 
multiple myeloma (MM), chronic lymphocytic 
leukemia (CLL), B-cell lymphoma (BCL)
AML: (64); ABC 
DLBCL: (70); MM: 
(71–73); CLL: (75); 
BCL: (102)
TLR10 Acute myeloid leukemia (AML), multiple 
myeloma (MM), chronic lymphocytic leukemia 
(CLL)
AML: (64); MM: 
(73); CLL: (75)
TLR11 Acute myeloid leukemia (AML), multiple 
myeloma (MM)
AML: (64); MM: (73)
TLR12 Acute myeloid leukemia (AML), multiple 
myeloma (MM)
AML: (64); MM: (73)
TLR13 Acute myeloid leukemia (AML), multiple 
myeloma (MM)
AML: (64); MM: (73)
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function. Furthermore, numerous recent studies have demon-
strated enhanced TLR expression and signaling in hematopoietic 
malignancies (Table  1). For example, activated TLR signaling 
and overexpression of TLRs and their downstream effectors are 
associated with MDS (11–15), a heterogeneous group of HSC 
disorders associated with ineffective hematopoiesis, myeloid 
dysplasia, and a high risk of transformation to acute leukemia. In 
addition, an activating mutation in MyD88 is commonly found 
in lymphoid malignancies (6–10, 46). While the exact role for 
this enhanced TLR signaling in these malignancies is not clear, 
it likely has, as with normal HSPCs, both cell-autonomous and 
non-autonomous effects on premalignant and malignant cells. 
Below, we discuss, in further detail, our current understanding 
of the role of TLR signaling in these and other hematopoietic 
malignancies and discuss the potential utility of TLR signaling as 
a therapeutic target in their treatment.
ABeRRANT TLR SiGNALiNG iN MDS
Myelodysplastic syndromes are a heterogeneous group of clonal 
HSC disorders characterized by peripheral cytopenias, myeloid 
dysplasia, and a high risk of transformation to acute leukemia 
(47). MDS is one of the most common hematopoietic malignan-
cies of older adulthood, and it occurs less frequently in children 
and young adults. The disease may occur de novo, or may arise 
following prior cytotoxic therapies. Distinct subtypes of MDS are 
identified based on genetic and morphological features, and in 
children MDS is often associated with inherited bone marrow 
failure syndromes (48). Regardless of the underlying genetic 
landscape, deregulation of innate immune signaling, and, in 
particular, enhanced TLR signaling, is associated with MDS 
(49, 50). Thus, TLRs and their downstream effectors are attrac-
tive therapeutic targets in MDS, as stem cell transplantation is 
presently the only curative therapy and is only feasible for a subset 
of patients (51).
Increased expression of multiple TLRs and signaling interme-
diates has been reported in MDS, as well as a loss of TLR signaling 
repressors. In patients with the deletion 5q (del (5q)) subtype of 
MDS, for example, loss of two micro-RNAs, miR-145 and miR-
146a, which normally inhibit the TLR signaling intermediates 
TIR-domain-containing adaptor protein (TIRAP that associates 
with MyD88 and assists in the formation of the Myddosome) 
and TRAF6, leads to inappropriate activation of TLR signaling 
(14). This, in turn, results in excessive IL-6 production, which 
contributes to ineffective hematopoiesis, including thrombocy-
tosis, megakaryocyte dysplasia, and neutropenia. Additionally, 
enforced expression of TRAF6 or knockdown of miR-145 or 
miR-146 in murine HSCs phenocopies some of the features of 
del (5q) MDS, suggesting that inappropriately activated TLR 
pathway signaling within the HSCs contributes to disease patho-
genesis (14). Recently, Varney et al. (13) described an additional 
mechanism for increased TRAF6 expression in del (5q) MDS 
involving haploinsufficiency for TRAF-interacting protein with 
forkhead-associated domain B (TIFAB). TIFAB forms a complex 
with TRAF6, reducing its stability by a lysosome-dependent 
mechanism, and mice transplanted with Tifab−/− HSPCs display 
a bone marrow failure like disease with cytopenias and myeloid 
differentiation skewing. Furthermore, re-expression of TIFAB in 
human MDS/AML cell lines with low endogenous TIFAB signifi-
cantly reduced leukemic colony formation and cell survival. Thus, 
along with miR-146a, TIFAB helps to limit TRAF6 expression 
and regulate HSPC differentiation and function.
In addition to the data supporting a role for enhanced TLR 
signaling in del (5q) MDS, numerous studies have shown 
increased expression of TLRs and TLR pathway intermediates 
in patients with all types of MDS. For example, Maratheftis and 
colleagues showed increased TLR4 expression in the CD34+ cells 
of patients with MDS in a small series of 21 cases, and this expres-
sion was associated with increased apoptosis (11). Velegraki 
and colleagues (52) found increased expression of TLR4 and 
upregulation of TLR4-mediated signaling in the CD14+ bone 
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marrow cells of patient with MDS. Furthermore, they reported 
that impaired clearance of apoptotic cells by macrophages in the 
bone marrow of patients with MDS is associated with increased 
circulating levels of the endogenous TLR agonist high mobility 
group protein B1 (HMGB1), and they concluded that this con-
tributes to enhanced proinflammatory cytokine production by 
monocytes and impaired clonogenic potential of CD34+ cells in 
MDS patients. More recently, Wei and colleagues demonstrated 
increased expression of TLR2 and its functional binding partners, 
TLR1 and TLR6, in the CD34+ cells of a series of 149 patients 
with MDS (15). Furthermore, they identified an acquired, acti-
vating variant of TLR2 (TLR2-F217S) in 11% of their cohort of 
individuals with MDS, which is associated with enhanced NF-κB 
activation in response to TLR2 ligand exposure. This group 
showed that inhibition of TLR2 in primary cultured bone marrow 
CD34+ cells from patients with MDS by short hairpin RNA led to 
improved erythroid colony formation in vitro, further supporting 
a role for this receptor in the pathogenesis of MDS. They proposed 
a model whereby augmented TLR2 signaling leads to activation 
of the histone demethylase JMJD3, thus stimulating the abnormal 
epigenetic activation of multiple innate immunity genes, includ-
ing IL-8, and promoting ineffective hematopoiesis. Based on these 
data, a phase I/II study of an anti-TLR2 antibody (OPN-305) is 
underway for second-line treatment of lower-risk MDS patients 
(Opsona Therapeutics, Dublin, Republic of Ireland).
Interestingly, while expression of TLR2 itself in the above 
study correlated with low-risk disease by the International 
Prognostic Scoring System and longer survival, higher expres-
sion of its binding partner, TLR6, was associated conversely with 
higher-risk disease and increased bone marrow blasts (15). This 
finding raises the intriguing possibility that the effects of TLR2 
signaling in MDS may be influenced by which heterodimer pair 
is stimulated (TLR1/2 versus TLR2/6). Historically, this associa-
tion with different partners has been thought to expand the ligand 
spectrum without altering downstream signaling (53). However, 
more recent data suggest that there are heterodimer-specific dif-
ferences with respect to activation of downstream pathways. For 
example, Rolf and colleagues (54) demonstrated that stimulation 
of acute lymphoblastic leukemia (ALL) cell lines and primary 
ALL samples with the specific TLR1/2 agonist, PAM3CSK4, 
versus the TLR2/6 agonist, PAM2CSK4, led to distinct activation 
kinetics of the NF-κB and PI3K pathways. Furthermore, only 
PAM3CSK4 sensitized ALL cells to vincristine-mediated toxic-
ity. Further studies are needed to determine whether there are 
heterodimer-specific effects of TLR2 stimulation on MDS cells, 
as this could have implications for the development of targeted 
therapies.
In addition to the TLRs themselves, the expression of numer-
ous downstream signaling mediators is increased in patients 
with MDS, as well. For example, increased expression of the TLR 
signaling adaptor, MyD88, was found in 40% of individuals in a 
cohort of 64 patients with MDS, and high expression correlated 
with shorter survival (16). Similarly, IRAK1 is overexpressed in 
the CD34+ cells of approximately 10–30% of patients with MDS, 
with high expression associated with reduced overall survival (12, 
55, 56). Pharmacologic or genetic inhibition of IRAK1 induced 
cell cycle arrest and apoptosis in MDS cells and improved survival 
in an MDS xenograft model (56), suggesting that IRAK1 may be 
a potential therapeutic target in MDS.
Thus, multiple studies have linked increased TLR signaling 
to MDS; however, the specific contribution of this signaling to 
disease progression is not clear. The existing data suggest that 
aberrant TLR signaling promotes ineffective hematopoiesis and 
likely contributes to the cytopenias characteristic of the disease. 
However, it is not at all clear whether this aberrant signaling 
promotes the transformation of MDS to acute leukemia. Further 
studies will be necessary to determine if TLR expression and 
signaling in premalignant MDS HSCs changes upon transforma-
tion, and whether TLR stimulation contributes to the acquisition 
of clonal dominance in this disease. In addition, it is not clear 
to what extent enhanced TLR signaling outside of the CD34+ 
population contributes to MDS pathogenesis. Accumulating 
evidence supports a role for the bone marrow microenvironment 
in the evolution of MDS, with numerous alterations in the bone 
marrow stromal and hematopoietic populations and deregulation 
of inflammatory cytokine secretion contributing to ineffective 
hematopoiesis. For example, myeloid-derived suppressor cells 
(MDSCs), an immature myeloid population with potent T-cell 
suppressive capabilities, are expanded in the bone marrow of 
MDS patients (57, 58). MDSCs were first characterized in tumor-
bearing mice and patients with cancer and contribute to immune 
escape of malignant cells. Notably, S100A9, which is a DAMP 
that is increased in the plasma of MDS patients and binds TLR2 
and TLR4, has been shown to stimulate the expansion and activa-
tion of MDSCs (57, 59, 60). S100A9 transgenic mice display an 
accumulation and activation of MDSCs and develop progressive 
multilineage cytopenias and dysplastic features characteristic of 
human MDS (57). Schneider and colleagues (61) also demon-
strated a link between haploinsufficiency of the ribosomal gene, 
Rps14, which has been linked to the severe macrocytic anemia 
observed in del (5q) MDS patients, to activation of the calcium 
binding proteins, S100A8 and S100A9. The authors found that 
S100A8, acting upstream of TLR4 and TNFα, contributed to a 
p53-dependent erythroid-differentiation defect. Further studies 
are needed to comprehensively define the different bone marrow 
populations in which aberrant TLR signaling occurs in MDS and 
to determine the relative contribution of cell-autonomous versus 
cell non-autonomous signaling to the disease pathogenesis.
TLR SiGNALiNG iN OTHeR MYeLOiD 
MALiGNANCieS
In addition to MDS, aberrant TLR expression has been associ-
ated with other myeloid neoplasms. For example, in a study 
of 103 newly diagnosed patients with acute myeloid leukemia 
(AML), Rybka and colleagues found that the mRNA expression 
of TLR2 and TLR4 was significantly higher in the bone marrow of 
patients with myelomonocytic and monoblastic acute leukemia 
compared to those with other types of AML. Furthermore, the 
expression of these receptors was also higher in patients with no 
response to induction therapy compared to those who achieved 
complete remission, and the overall survival of patients with 
higher TLR2 and TLR4 expression was significantly shorter than 
that of patients with lower expression (62). One of the binding 
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partners of TLR2, TLR1, was also shown to be significantly 
upregulated in leukemic stem cells (LSCs) derived from 18 AML 
patients as compared to normal bone marrow cells derived from 
healthy donors, a finding consistent with elevated TLR1 mRNA 
levels observed in MDS patients described earlier (15, 63). 
The authors stimulated LSCs both in vitro and ex vivo with the 
TLR2/1 agonist, PAM3CSK4, and found that agonist treatment 
led to expansion, increased leukemic cell survival, and a shift 
toward differentiation. Similarly, in a study of mRNA expression 
of TLRs in myeloid leukemia cell lines, Okamoto and colleagues 
found that 10 TLRs were expressed in the majority of leukemic 
cell lines assessed (64). The authors evaluated the functionality 
of the TLRs by examining cell proliferation and differentiation 
upon ligand exposure. Ligand stimulation, however, failed to 
trigger differentiation (contrary to what was observed in normal 
bone marrow progenitors), thereby warranting further study of 
the mechanism through which TLR signaling induces differen-
tiation in normal and malignant cells.
TLR SiGNALiNG iN LYMPHOiD 
MALiGNANCieS
In addition to myeloid malignancies, enhanced TLR signaling 
has been implicated in a number of lymphoid neoplasms as 
well. Notably, lymphoid malignancies are commonly associated 
with a specific gain-of-function mutation in MyD88. This single 
nucleotide variant leads to the substitution within the MyD88 
TIR domain of a leucine residue at position 265 to a proline 
(L265P), which ultimately promotes enhanced IRAK1 phos-
phorylation and activation of NF-κB and JAK–STAT3 signaling 
with production of proinflammatory cytokines and promotion 
of cell survival (6, 65). MyD88 (L265P) is highly recurrent, with 
29% of a cohort of 382 patients with activated B-cell-like diffuse 
large B-cell lymphoma possessing this mutation (6). The same 
mutation was found in 9% of gastric mucosa-associated lymphoid 
tissue (MALT) lymphomas. It was also identified in 2.9% of 
patients with chronic lymphocytic leukemia and was associated 
with younger age and more advanced clinical stage (7). Finally, 
the L265P MyD88 mutation was found in nearly 50% of patients 
with immunoglobulin M (IgM) monoclonal gammopathy of 
unknown significance (MGUS) and >90% (66) of patients with 
Waldenstrom macroglobulinemia (WM) (9, 10). In addition to 
activating IRAK activity, Yang and colleagues (67) found that 
the MyD88 (L265P) variant supports lymphoplasmacytic cell 
survival in WM through stimulation of Bruton tyrosine kinase 
(BTK), and suppression of BTK and IRAK1/2 had synergistic 
effects on inhibiting NF-κB signaling and promoting apoptosis 
in WM cells. In a study utilizing a retroviral gene transfer system 
in mice, Wang and colleagues (68) demonstrated that the MyD88 
(L265P) variant alone was capable of driving B cell division 
in vitro in the absence of exogenous TLR ligands. However, this 
proliferation was dependent upon intact signaling by the RNA/
DNA-sensing TLRs, as it was inhibited by the Unc93b13d mutation 
(which disrupts exogenous antigen presentation and signaling 
via TLRs 3, 7, and 9) (66, 69), TLR9 deficiency, and chloroquine 
exposure (necessary for proteolytic activation of TLR ectodo-
mains). The dependence of oncogenic MyD88 on TLRs has also 
been suggested in activated B-cell (ABC) diffuse large B-cell 
lymphoma (DLBCL), where both the depletion of a number of 
proteins necessary for TLR7 and TLR9 trafficking and signaling, 
including UNC93B1, CD14, and PRAT4A, and pharmacologic 
inhibitors of these TLRs led to cell death in vitro (70).
In addition to the activating MyD88 (L265P) mutation, the 
expression of TLR signaling pathway components is increased 
in lymphoid malignancies. For example, TLRs have been found 
to be more highly expressed in the plasma cells obtained from 
multiple myeloma patients as compared to healthy control donors 
(71). Additionally, culture of human myeloma cell lines and 
primary cells with TLR ligands stimulates cell growth and spares 
these cells from serum deprivation or dexamethasone-induced 
apoptosis via autocrine secretion of interleukin-6 (IL-6) (71–73). 
In a study of Mantle cell lymphoma (MCL), an incurable B-cell 
malignancy, Wang and colleagues found that the levels of TLR4 
expression were significantly higher on primary MCL cells than 
normal peripheral blood mononuclear cells (PBMCs) or B cells, 
and activation of TLR4 by LPS promotes tumor growth and 
enables MCL cells to evade the immune system via secretion 
of IL-6, IL-10, and vascular endothelial growth factor (VEGF) 
(74). A study of TLR expression patterns in purified leukemic 
B-lymphocytes isolated from chronic lymphocytic leukemia 
(CLL) patients and the MEC1 CLL cell line revealed an increased 
expression of TLRs 1, 2, 6, 7, 9, and 10 (75). Further in  vitro 
studies demonstrated that the TLR2/1 and TLR2/6 ligands, 
PAM3CSK4 and MALP-2 (mycoplasmal macrophage-activating 
lipopeptide-2), protected CLL cells from spontaneous apoptosis. 
Finally, single nucleotide polymorphisms (SNPs) in several TLRs 
have been associated with lymphoma risk (76–79).
TLR SiGNALiNG iN NON-HeMATOPOieTiC 
MALiGNANCieS
While a detailed discussion of the role of TLR signaling in 
non-hematopoietic malignancies is outside the scope of this 
review, cell-intrinsic signaling for a number of TLRs has been 
associated with promoting oncogenesis (80). For example, TLR2 
has recently been shown to have a cell-intrinsic role in regulating 
epithelial cell growth and oncogenesis. Scheeren and colleagues 
(81) reported that loss of TLR2 signaling in intestinal epithelium 
reduces damage-induced colitis regeneration and spontaneous 
tumor formation in Apcmin/+ mice [carrying a point mutation 
in the adenomatous polyposis coli (Apc) gene, which leads to 
development of intestinal tract tumors]. Furthermore, TLR2 is 
expressed on breast epithelia, and TLR2 agonist treatment of 
luminal and basal breast epithelial cells promotes in vitro colony 
growth. Conversely, TLR2 loss inhibited the growth of breast can-
cer cells both in vitro and in vivo. Another recent study showed 
that STAT3-mediated upregulation of TLR2 expression on gastric 
epithelial cells promoted cell proliferation and survival, and inhi-
bition of TLR2 suppressed gastric tumor formation (82). Cherfils-
Vicini et al. (83) demonstrated expression of TLR7 and TLR8 in 
human primary lung cancer sections and lung tumor cell lines and 
showed that stimulation of these cell lines in culture with TLR7 
and TLR8 agonists led to activation of NF-κB, as well as increased 
expression of the anti-apoptotic protein Bcl-2, enhanced survival, 
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and chemoresistance. Additionally, He and colleagues described 
the expression of functional TLR4 in human lung cancer cells (84) 
and found that TLR4 stimulation led to the secretion of numerous 
immunosuppressive cytokines, including VEGF and TGF-β, and 
the proangiogenic chemokine IL-8, thereby inducing resistance 
to TNFα and TRAIL-induced apoptosis in  vitro. Finally, high 
TLR9 expression was also observed in both primary lung cancer 
specimens and tumor cell lines (85), and activation of the TLR9 
pathway resulted in the production of monocyte chemoattractant 
protein-1 (MCP-1) and the reduction of TNFα-induced apopto-
sis. Together, these data from non-hematopoietic malignancies 
support a role for cell-autonomous TLR signaling in promoting 
the growth and survival of malignant cells.
TLRs AS THeRAPeUTiC TARGeTS 
iN HeMATOPOieTiC MALiGNANCY
Treatment of hematopoietic malignancies is still largely based 
on chemotherapeutic drug regimens and stem cell transplanta-
tion, and new therapies are needed. The association of enhanced 
TLR expression and signaling with hematopoietic malignancies 
suggests that inhibition of these receptors or their downstream 
effectors may confer therapeutic benefit. As discussed above, for 
example, a phase I/II study of an anti-TLR2 antibody (OPN-305, 
Opsona Therapeutics, Dublin, Ireland) is currently underway for 
the second-line treatment of lower-risk MDS patients based on 
preclinical studies showing improved erythroid colony formation 
upon TLR2 inhibition in MDS CD34+ cells in vitro. Similarly, as 
the activating MyD88 L265P mutation is prevalent in multiple 
lymphoid malignancies, particularly WM, inhibiting this factor 
represents an attractive therapeutic strategy. Indeed, preclinical 
studies have shown that loss of MyD88 or its downstream targets 
(BTK, IRAK1, IRAK4) suppresses NF-κB signaling and induces 
WM cell death. Ibrutinib is a BTK inhibitor that was recently 
approved for the treatment of WM following a prospective, 
multicenter trial that showed its efficacy with high response rates 
and improved progression-free survival in previously treated 
patients (46, 86).
Although the role of TLR signaling in hematopoietic malig-
nancies is largely thought to be that of promoting disease, as 
reviewed above, and inhibitors of TLR signaling, such as OPN-305 
and Ibrutinib, currently offer therapeutic promise, accumulating 
evidence actually supports a potential role for TLR agonists in the 
treatment of some hematopoietic malignancies as well. Recent 
work by Ignatz-Hoover and colleagues (87), for example, demon-
strated that the TLR7/8 agonist R848 promotes in vitro terminal 
differentiation and inhibits proliferation of AML cell lines and 
primary patient samples in a TLR8–MyD88–p38-dependent 
fashion. Furthermore, R848 significantly inhibited AML tumor 
growth in an AML NSG mouse xenograft model. In human 
myeloma cell lines, stimulation with polyinosinic–polycytidylic 
acid (poly I:C), an agonist of TLR3, led to increased apoptosis and 
induced activation of the NFκB pathway and type I IFN secretion, 
thereby inhibiting cell growth. Poly I:C also led to TLR3 upregula-
tion, type I IFN induction, and increased apoptosis in primary 
AML cells (88, 89). Similarly, treatment of ALL cell lines and pri-
marily ALL samples with the specific TLR2/1 ligand, PAM3CSK4, 
triggered caspase-8-mediated apoptosis and sensitized ALL cells 
to vincristine-mediated toxicity in vitro (54). These studies sup-
port the idea that cell-autonomous TLR signaling may, in fact, 
have an antitumor effect in some hematopoietic malignancies.
In addition to a potential direct antitumor effect, TLR agonists 
are being used in multiple tumor types, including hematopoietic 
malignancies, for their ability to elicit anticancer immune 
responses (90–95). In this respect, TLR agonists act to disrupt 
tolerance to tumor cells, thus facilitating the destruction of these 
cells by the patient’s own immune system. As early as the 1960s, 
Mathe and colleagues described enhanced survival in pediatric 
leukemia patients treated with injections of the TLR agonist, 
Bacille Calmette–Guérin (BCG) bacilli, which is still currently 
utilized for the treatment of bladder cancer (96–98). The majority 
of clinical trials utilizing TLR agonists have focused on TLR3, 
TLR7/8, and TLR9, and recent studies have indicated that the 
combinatorial use of TLR agonists may be beneficial for patients 
whose tumors express multiple TLRs (99–101). With respect to 
hematologic malignancies, three phase I/II clinical trials are cur-
rently recruiting patients to study the potential use of TLR3, TLR4, 
and TLR9 agonists in combination with immunotherapeutics and 
radiation therapy for the treatment of recurrent low-grade B-cell 
lymphomas, T-cell lymphoma, and follicular non-Hodgkin’s lym-
phoma (Clinical Trial Identifiers: NCT02254772, NCT02501473, 
and NCT01976585) (102–104).
SUMMARY AND FUTURe DiReCTiONS
Toll-like receptors have a well-established role in innate immunity 
and inflammation upon stimulation by foreign pathogens and 
endogenous DAMPS. The type of ligand, in part, dictates both the 
subcellular localization of the TLR and the unique downstream 
signaling pathways that are activated, leading to numerous cel-
lular effects, including cytokine secretion and regulation of gene 
expression. While the role of TLR signaling in committed effector 
immune cells has been extensively studied, recent evidence sug-
gests these receptors can also influence earlier precursor HSC and 
progenitor populations. The expression of multiple TLRs has been 
described in normal HSCs as well as in stromal cells of the bone 
marrow niche. Upon stimulation, TLRs either directly activate 
HSCs or act indirectly on them through the production of pro-
inflammatory cytokines by bone marrow niche cells or immune 
effector cells (Figure 2). While some degree of TLR signaling may 
be essential for the development of a normal immune response, 
accumulating data show an association between enhanced TLR 
expression and signaling and hematopoietic disorders and malig-
nancies, such as MDS and lymphoid neoplasms (Table 1).
As discussed herein, numerous studies have linked altered 
TLR signaling to hematopoietic dysfunction and malignancy, 
supporting a role for this signaling in the pathogenesis of these 
diseases. However, in many cases, questions remain regarding the 
etiology of the increased TLR expression and signaling and the 
precise contribution of this signaling to the initiation and/or pro-
gression of disease. Inflammatory signals themselves, including 
cytokines such as IFN-gamma and G-CSF and TLR ligands such 
as LPS, have been shown to upregulate TLR expression on various 
bone marrow cell types (42, 105–108). Thus, a proinflammatory 
FiGURe 2 | TLR signaling influences both normal and premalignant HSCs. TLR agonists may both directly (solid lines) and indirectly (dashed lines) influence 
HSCs. In normal HSCs, TLR signals promote myeloid differentiation and mobilization, and sustained exposure to TLR agonists can result in reduced HSC function. 
In MDS and other hematopoietic malignancies, enhanced TLR signaling (via increased expression or, in the case of MDS, acquisition of the activating TLR2-F217S 
variant or increased TRAF6 activity in 5q- cases) may contribute to ineffective hematopoiesis and leukemogenesis.
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tumor microenvironment could contribute to the increased 
TLR expression seen in multiple hematopoietic malignancies. 
Furthermore, for some TLRs, including TLR2, 4, and 5, mem-
brane receptor expression shifts to cytoplasmic during dysplastic 
transformation in solid tumors (109). In addition, endogenous 
ligands, including HMGB1, are capable of translocating to the 
cytoplasm upon malignant transformation (109, 110), suggesting 
the possibility that alterations in the subcellular locations of TLRs 
and their ligands could contribute to enhanced TLR signaling in 
hematopoietic malignancies. Further studies will be needed to 
investigate these ideas and determine the factors that influence 
TLR expression and signaling in premalignant and malignant 
hematopoietic cells.
In addition to questions regarding the stimulus for enhanced 
TLR expression and signaling in hematopoietic neoplasms, in 
many cases, the significance of this signaling to the pathogenesis of 
disease is not well understood, and additional studies are needed 
to determine the effects of augmenting or inhibiting TLR signal-
ing on disease outcomes (i.e., severity of cytopenias, and initiation 
and/or progression of leukemia). Furthermore, while multiple 
different TLRs have been shown to have elevated expression in 
various tumors, it is not clear to what extent these different recep-
tors may confer unique signals leading to the promotion of tumor 
development (In other words, does all TLR signaling generally 
have the same impact on premalignant and malignant cells, or do 
different TLRs ultimately influence downstream mediators that are 
unique to particular receptors?). Furthermore, the downstream 
mediators of TLR signaling that regulate HSC cycling, differen-
tiation, and function, and that ultimately therefore may promote 
leukemogenesis, are not well known. And finally, the contribution 
of cell-autonomous versus cell non-autonomous TLR signaling 
to hematopoietic malignancies is not well understood. Although 
the expression and signaling of TLRs is known to be increased 
on the CD34+ cells of MDS patients, for example, as well as the 
leukemia cells in various myeloid and lymphoid cancers, it is not 
known whether other cell types within the bone marrow micro-
environment (hematopoietic and stromal) also display aberrant 
TLR signaling, and what role this non-autonomous signaling may 
play in the pathogenesis of the disease.
In line with the lack of detailed understanding of the role 
of TLR signaling in many hematopoietic malignancies, several 
questions remain regarding the utility of targeting these receptors 
therapeutically. As discussed above, TLR expression and signaling 
is generally enhanced in hematopoietic neoplasms, and therefore 
inhibition of TLR signaling is a logical therapeutic strategy. While 
TLR antagonists are under investigation currently in select cases 
(OPN-305 in MDS and Ibrutinib in WM, for example), there 
are multiple studies conversely showing an antitumor effect of 
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TLR stimulation, with TLR agonists either directly affecting cell 
growth and chemosensitivity or indirectly supporting tumor 
cell death via promotion of an antitumor immune response. A 
more defined understanding of the mechanism through which 
TLRs influence hematopoietic neoplasms is therefore necessary 
to better delineate the utility of TLR agonists versus antagonists 
as novel therapeutic options and balance the potential benefits 
of reducing hyperactivated TLR signaling on hematopoiesis with 
the risks of suppressing the immune response against the tumor 
cells as well as infections (111).
Based on the studies discussed within, it has become increas-
ingly apparent that the effects of TLR signaling on tumor growth 
and progression requires careful consideration of numerous 
factors, including the TLR in question, unique downstream 
effectors, the influence of the tumor microenvironment, and the 
tumor type. Future studies aimed at gaining a comprehensive 
mechanistic understanding of the role of TLR signaling in 
lymphoproliferative disorders, MDS, and other hematopoietic 
neoplasms are required to more fully appreciate the influence 
of this signaling on disease pathogenesis and determine the 
appropriate utility of TLR agonists and antagonists as thera-
peutic agents.
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